Article Text

Download PDFPDF
Testosterone supplementation did not prevent cognitive decline or increase bone mineral density in older men

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dr M H Emmelot-Vonk

Correspondence to: Dr M H Emmelot-Vonk, University Medical Center, Utrecht, The Netherlands;



randomised, placebo controlled trial.




blinded (participants and clinicians).†



University Medical Centre in Utrecht, the Netherlands.


237 men 60–80 years of age (mean age 67 y) who had testosterone concentrations <13.7 nmol/l (394.8 ng/dl). Exclusion criteria included myocardial infarction or cerebrovascular accident in the past 6 months; heart failure unless medically treated and not symptomatic; cancer in the past 5 years except non-melanoma skin cancer and hormone dependent tumor; renal or liver disease; haematological abnormalities; epilepsy or use of antiepileptic medication; >1 migraine per month; diabetes mellitus; fasting glucose concentration ⩾6.9 mmol/l (124 mg/dl); corticosteroid use (⩾7.5 mg/d in the past 6 mo except for prednisolone use …

View Full Text


  • Source of funding: The Netherlands Organization for Health Research and Development. Trial medication was provided by Organon NV (Oss, The Netherlands).